Roles of inflammatory biomarkers in the evaluation of clinical outcomes in chronic heart failure

doi:10.3760/cma.j.cn441417-20240531-01009

Abstract

Abstract:

Inflammation participates in the development of chronic heart failure. Traditional inflammatory markers, represented by C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and procalcitonin (PCT), have important value in the prognosis evaluation of chronic heart failure. In recent years, with the continuous deepening of the research, novel composite inflammatory markers such as neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), monocyte to high-density lipoprotein cholesterol ratio (MHR), systemic immune-inflammatory index (SII) have become research hotspots. Compared to the traditional inflammatory markers, their performances are more stable in chronic heart failure, which are expected to provide a new reference for the clinical diagnosis and treatment of chronic heart failure.

Key words:

Chronic heart failure, Traditional inflammatory biomarkers, Novel composite inflammatory markers, Progress

摘要：

炎症参与慢性心力衰竭的发生发展。传统的炎症标志物以C反应蛋白（C-reactive protein，CRP）、肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）、白细胞介素-6（interleukin-6，IL-6）、降钙素原（procalcitonin，PCT）等为代表，在慢性心力衰竭预后评估中有重要价值。近年来，随着研究的不断深入，新型复合型炎症标志物如中性粒细胞与淋巴细胞比值（neutrophil to lymphocyte ratio，NLR）、淋巴细胞与单核细胞比值（lymphocyte to monocyte ratio，LMR）、血小板与淋巴细胞比值（platelet to lymphocyte ratio，PLR）、单核细胞与高密度脂蛋白胆固醇比值（monocyte to HDL cholesterol ratio，MHR）、系统免疫炎症指数（systemic immune-inflammatory index，SII）成为研究的热点，相比于传统炎症标志物，其在慢性心力衰竭中的表现更稳定，有望为慢性心力衰竭患者的临床诊治提供新的参考。

关键词:

慢性心力衰竭, 传统炎症标志物, 新型复合型炎症标志物, 进展

Jiang Zejun, Tang Shengyu, Yang Hongling.

Roles of inflammatory biomarkers in the evaluation of clinical outcomes in chronic heart failure [J]. International Medicine and Health Guidance News, 2025, 31(1): 42-46.

姜泽军汤胜宇杨红玲.

炎症标志物在慢性心力衰竭临床预后评估中的作用 [J]. 国际医药卫生导报, 2025, 31(1): 42-46.

References

[1] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52(3):235-275. DOI:10.3760/cma.j.cn112148-20231101- 00405.
[2] Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure[J]. Cardiovasc Drugs Ther, 2020, 34(6):849-863. DOI: 10.1007/s10557-020-07071-0.
[3] Lin XL, Sun HX, Li FQ, et al. Admission high-sensitivity C-reactive protein levels improve the Grace risk score prediction on in-hospital outcomes in acute myocardial infarction patients[J]. Clin Cardiol, 2022, 45(3):282-290. DOI: 10.1002/clc.23749.
[4] Wang Q, An Y, Wang H, et al. The clinical significance of changes in cTnT, CRP and NT-proBNP levels in patients with heart failure[J]. Am J Transl Res, 2021, 13(4):2947-2954.
[5] Proute MC, Kothur N, Georgiou P, et al. The effect of statin therapy on inflammatory biomarkers: a systematic review[J]. Cureus, 2021, 13(9):e18273. DOI: 10.7759/cureus.18273.
[6] Kang S, Fan LY, Chen M, et al. Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure[J]. Curr Vasc Pharmacol, 2017, 15(4):390-396. DOI: 10.2174/1570161115666170404121619.
[7] 陈曦,崔丽丽,张然,等.C反应蛋白检测与应用的研究进展[J].检验医学与临床,2023,20(8):1139-1142. DOI:10.3969/j.issn.1672-9455.2023.08.027.
[8] DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction[J]. PLoS One, 2018, 13(8):e0201836. DOI: 10.1371/journal.pone.0201836.
[9] Halestrap AP, Richardson AP. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury[J]. J Mol Cell Cardiol, 2015, 78:129-141. DOI: 10.1016/j.yjmcc.2014.08.018.
[10] 思飞,甄玲玲,王映珍,等.艾司洛尔对脓毒症大鼠心肌细胞凋亡影响的实验研究[J].第三军医大学学报,2020,42(13):1292-1300. DOI:10.16016/j.1000-5404.202002145.
[11] 郭萌薇.慢性心力衰竭患者血清B型利钠肽、同型半胱氨酸以及炎性因子与心功能相关性分析[J].中国卫生检验杂志,2020,30(11):1376-1377,1387.
[12] Zheng Y, Li Y, Ran X, et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway[J]. Cell Mol Life Sci, 2022, 79(6):311. DOI: 10.1007/s00018-022-04331-0.
[13] Li J, Wang T, Liu P, et al. Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD[J]. Food Funct, 2021, 12(9):3898-3918. DOI: 10.1039/d0fo02736g.
[14] Han F, Li S, Yang Y, et al. Interleukin-6 promotes ferroptosis in bronchial epithelial cells by inducing reactive oxygen species-dependent lipid peroxidation and disrupting iron homeostasis[J]. Bioengineered, 2021, 12(1):5279-5288. DOI: 10.1080/21655979.2021. 1964158.
[15] 胡哲夫,唐其柱,冯一洲,等.IL-6在心血管疾病中的研究进展[J].国际心血管病杂志,2024,51(1):7-10. DOI:10.3969/j.issn.1673-6583.2024.01.003.
[16] Perez AL, Grodin JL, Chaikijurajai T, et al. Interleukin-6 and outcomes in acute heart failure: an ASCEND-HF substudy[J]. J Card Fail, 2021, 27(6):670-676. DOI: 10.1016/j.cardfail.2021.01.006.
[17] Huo S, Shi W, Ma H, et al. Alleviation of inflammation and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via IL-6/STAT3 inhibition by raloxifene[J]. Oxid Med Cell Longev, 2021, 2021:6699054. DOI: 10.1155/2021/6699054.
[18] 曾清清,高忠兰,陈务贤,等.高盐诱导高血压大鼠心肌间质重构及SHIP-1和IL-6的表达研究[J].广西医科大学学报,2023,40(1):54-58. DOI:10.16190/j.cnki.45-1211/r.2023.01.009.
[19] 陈坤成,占凌辉,谢芳.慢性阻塞性肺疾病急性加重期合并心力衰竭患者CRP和NT-proBNP水平检测及其意义[J].慢性病学杂志,2020,21(5):720-722,725. DOI:10.16440/j.cnki.1674-8166.2020.05.028.
[20] Gao L, Liu X, Zhang D, et al. Early diagnosis of bacterial infection in patients with septicopyemia by laboratory analysis of PCT, CRP and IL-6[J]. Exp Ther Med, 2017, 13(6):3479-3483. DOI: 10.3892/etm.2017.4417.
[21] 任凯,冯津萍,陈树涛,等.慢性心力衰竭患者血清hs-cTnT、 NT-proBNP、hs-CRP表达水平与心功能相关性研究[J].中国心血管病研究,2017,15(12):1094-1097. DOI:10.3969/j.issn.1672-5301.2017.12.011.
[22] Treistman N, Cavalcante LBCP, Gonzalez F, et al. Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients[J]. Endocrine, 2023, 81(1):141-148. DOI: 10.1007/s12020-023-03340-8.
[23] Maloney S, Pavlakis N, Itchins M, et al. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as biomarkers in resected pancreatic cancer[J]. J Clin Med, 2023, 12(5):1989. DOI: 10.3390/jcm12051989.
[24] Davison BA, Takagi K, Edwards C, et al. Neutrophil-to-lymphocyte ratio and outcomes in patients admitted for acute heart failure (as seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF studies) [J]. Am J Cardiol, 2022, 180:72-80. DOI: 10.1016/j.amjcard.2022.06.037.
[25] Cho JH, Cho HJ, Lee HY, et al. Neutrophil-lymphocyte ratio in patients with acute heart failure predicts in-hospital and long-term mortality[J]. J Clin Med, 2020, 9(2):557. DOI: 10.3390/jcm9020557.
[26] Tamaki S, Nagai Y, Shutta R, et al. Combination of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of cardiac death in patients with acute decompensated heart failure with preserved left ventricular ejection fraction: a multicenter study[J]. J Am Heart Assoc, 2023, 12(1):e026326. DOI: 10.1161/JAHA.122.026326.
[27] Lin M, Zhan J, Luan Y, et al. Development and validation of a risk score in Chinese patients with chronic heart failure[J]. Front Cardiovasc Med, 2022, 9:865843. DOI: 10.3389/fcvm.2022.865843.
[28] Widmer A, Linka AZ, Attenhofer Jost CH, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia[J]. Cardiology, 2003, 99(1):25-31. DOI: 10.1159/000068448.
[29] Chávez-Sánchez L, Espinosa-Luna JE, Chávez-Rueda K, et al. Innate immune system cells in atherosclerosis[J]. Arch Med Res, 2014, 45(1):1-14. DOI: 10.1016/j.arcmed.2013.11.007.
[30] Silva N, Bettencourt P, Guimarães JT. The lymphocyte-to-monocyte ratio: an added value for death prediction in heart failure[J]. Nutr Metab Cardiovasc Dis, 2015, 25(11):1033-1040. DOI: 10.1016/j.numecd.2015.07.004.
[31] Delcea C, Buzea CA, Vîjan AE, et al. The platelet to lymphocyte ratio in heart failure: a comprehensive review[J]. Rom J Intern Med, 2023, 61(2):84-97. DOI: 10.2478/rjim-2023-0006.
[32] Getawa S, Bayleyegn B. Platelet, neutrophil and lymphocyte quantitative abnormalities in patients with heart failure: a retrospective study[J]. Vasc Health Risk Manag, 2023, 19:69-78. DOI: 10.2147/VHRM.S394765.
[33] 陈怡卉,龚燕锋.血小板/淋巴细胞比值与心血管系统疾病的相关研究进展[J].实用老年医学,2023,37(9):956-959,972. DOI:10.3969/j.issn.1003-9198.2023.09.022.
[34] Joury A, Ventura H, Krim SR. Biomarkers in heart failure: relevance in the clinical practice[J]. Int J Cardiol, 2022, 363:196-201. DOI: 10.1016/j.ijcard.2022.06.039.
[35] 冯惠平,解俊敏,张靖,等.急性冠脉综合征白蛋白、中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的变化及意义[J].中国老年学杂志,2021,41(3):456-459. DOI:10.3969/j.issn.1005-9202.2021.03.003.
[36] 黄志珊,黄广军,赵钟烈.舒张性心力衰竭患者中检测血小板/淋巴细胞比值价值分析[J].当代临床医刊,2022,35(3):1-2. DOI:10.3969/j.issn.2095-9559.2022.03.01.
[37] Chen BW, Liu JJ, Xing JH, et al. Analysis of the correlation between the ratio of monocytes to high-density lipoprotein cholesterol and in-stent restenosis in patients with premature coronary heart disease[J]. Clin Appl Thromb Hemost, 2022, 28:10760296221079334. DOI: 10.1177/10760296221079334.
[38] 杨小利,徐宏,阮森林.单核细胞/高密度脂蛋白比值在心力衰竭诊断中的应用价值[J].中国卫生检验杂志,2022,32(4):472-474,478.
[39] 王莹,吴少敏,马贵洲,等.单核细胞/高密度脂蛋白胆固醇比值与绝经后女性冠心病患者急性心力衰竭的关系[J].中国动脉硬化杂志,2020,28(10):899-904. DOI:10.3969/j.issn.1007-3949.2020.10.014.
[40] Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23):6212-6222. DOI: 10.1158/1078-0432.CCR-14-0442.
[41] Keit E, Coutu B, Zhen W, et al. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer[J]. Ann Transl Med, 2021, 9(3):227. DOI: 10.21037/atm-20-6710.
[42] Topcuoglu MA, Pektezel MY, Yilmaz E, et al. Systemic inflammation indices in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: clinical yield and utility[J]. Angiology, 2021, 72(3):279-284. DOI: 10.1177/0003319720969997.
[43] 黎晨辉,杨少芬,卢庆莉,等.系统免疫炎症指数与慢性心力衰竭急性发作患者院内死亡的相关性研究[J].心肺血管病杂志,2021,40(7):658-662. DOI:10.3969/j.issn.1007- 5062.2021.07.003.
[44] Yuan M, Ren F, Gao D. The value of SII in predicting the mortality of patients with heart failure[J]. Dis Markers, 2022, 2022:3455372. DOI: 10.1155/2022/3455372.
[45] Tang Y, Zeng X, Feng Y, et al. Association of systemic immune-inflammation index with short-term mortality of congestive heart failure: a retrospective cohort study[J]. Front Cardiovasc Med, 2021, 8:753133. DOI: 10.3389/fcvm.2021.753133.
[46] 陈艳丽,帕尔哈提·吐尔逊.系统免疫炎症指数与心血管疾病相关性研究进展[J].兵团医学,2023,21(2):52-55. DOI:10.3969/j.issn.1672-4356.2023.02.027.